Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc covers the period ending February 2015. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), or connected persons, specifically regarding the vesting of conditional share awards.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific equity transaction:
- Closing Share Price: £14.855 per Ordinary Share (as of February 12, 2015).
- Transaction Type: Vesting and lapping of Performance Share Plan awards.
Material Changes
The filing details the outcome of a three-year performance period for a 2009 Performance Share Plan award made in 2012 to a connected person of a PDMR. The performance period ran from January 1, 2012, to December 31, 2014. On February 12, 2015, the following occurred:
| PDMR | Connected Person | Shares Awarded | Shares Lapsed |
|---|---|---|---|
| Mr P Thomson | Mrs K Thomson | 574 | 1,693 |
The filing does not provide comparative data against prior periods for these specific metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a share plan transaction under Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Checklist
- Verify the total number of shares vested versus lapsed for the specific award to understand the performance condition outcome.
- Confirm the share price of £14.855 against market data for February 12, 2015.
- Review the full 2009 Performance Share Plan terms to understand the specific business performance conditions that led to the lapse of 1,693 shares.
- Note that this filing does not contain operational or financial results for the company; refer to Form 20-F for comprehensive financial data.